The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
Open accessAbstract
Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin.Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies.Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.Trial registration: ClinicalTrials.gov identifier: NCT00290563.Trial registration: ClinicalTrials.gov identifier: NCT00835718.Trial registration: ClinicalTrials.gov identifier: NCT03282591.Trial registration: ClinicalTrials.gov identifier: NCT01951274.Trial registration: ClinicalTrials.gov identifier: NCT02196324.Trial registration: ClinicalTrials.gov identifier: NCT02975206.Trial registration: ClinicalTrials.gov identifier: NCT03343639.Trial registration: ClinicalTrials.gov identifier: NCT03546816.Trial registration: ClinicalTrials.gov identifier: NCT03677401.Trial registration: ClinicalTrials.gov identifier: NCT03540160.Trial registration: ClinicalTrials.gov identifier: NCT03841331.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this conclusion may not be generalized for a number of itchy skin disorders such as prurigo nodularis in which targeting itch remains promising193,205,210–212.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [210]
Citations
Cites
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628
Yosipovitch, G., & Bernhard, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1208814 · Cited by 405
Self-citationEuropean S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Self-citationWhy we scratch an itch: the molecules, cells and circuits of itch
Bautista, D. M., Wilson, S. R., & Hoon, M. A. (2014) · Nature Neuroscience · doi:10.1038/nn.3619 · Cited by 338
The Impact of Pruritus on Quality of Life: The Skin Equivalent of Pain
Kini, S. P. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.178 · Cited by 324
Nattkemper, L. A., Tey, H. L., Valdes-Rodriguez, R., Lee, H., Mollanazar, N. K., Albornoz, C., Sanders, K. M., & Yosipovitch, G. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.12.029 · Cited by 310
Self-citationTargeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
Ständer, S., Siepmann, D., Herrgott, I., Sunderkötter, C., & Luger, T. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010968 · Cited by 293
Self-citationMatterne, U., Apfelbacher, C., Loerbroks, A., Schwarzer, T., Büttner, M., Ofenloch, R., Diepgen, T., & Weisshaar, E. (2011) · Acta Dermato Venereologica · doi:10.2340/00015555-1159 · Cited by 264
Andoh, T., Nagasawa, T., Satoh, M., & Kuraishi, Y. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37703-1 · Cited by 233
Ständer, S., Schäfer, I., Phan, N. Q., Blome, C., Herberger, K., Heigel, H., & Augustin, M. (2010) · Dermatology · doi:10.1159/000319862 · Cited by 206
Self-citation
Research works printed but not linked: 3
- Saco M, 2015, J Fam Pract, 64, 221
- Andoh T, 1998, J Pharmacol Exp Ther, 286, 1140
- 2019, Data on file
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Kader, H. A., Azeem, M., Jwayed, S. A., Al-Shehhi, A., Tabassum, A., Ayoub, M. A., Hetta, H. F., Waheed, Y., Iratni, R., Aldhaheri, A., et al. (2021) · Cells · doi:10.3390/cells10061392 · Cited by 105
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
“In patients with chronic prurigo, serlopitant also significantly reduced pruritus in a phase-2 study; however, it numerically but not significantly reduced pruritus in two phase-3 studies (32).”
BackgroundMolecular mechanisms of pruritus in prurigo nodularis
Shao, Y., Wang, D., Zhu, Y., Xiao, Z., Jin, T., Peng, L., Shen, Y., & Tang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301817 · Cited by 63
“Substance P (SP), secreted by sensory neurons, plays an important role in itch signaling within the peripheral and central nervous systems (65, 66).”
BackgroundInvolvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions
Ruppenstein, A., Limberg, M. M., Loser, K., Kremer, A. E., Homey, B., & Raap, U. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.627985 · Cited by 57
Metadata
- Authors
- Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G.
- Affiliations
- University Hospital Münster (DE)
- Vyne Therapeutics (United States) (US)
- University of Miami (US)
- Corresponding author
- Ständer, Sonja
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-07-04
- Volume
- 28
- Issue
- 8
- Pages
- 659-666
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2954505358
- Cited by
- 26
- References
- 45
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 5 · 2022: 2 · 2021: 7 · 2020: 5
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Menlo Therapeutics (NA)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Urticaria and Related Conditions
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- chronic pruritus, NK1 receptor antagonists, prurigo nodularis, drug development, treatment efficacy and safety, unmet medical needs, quality of life
- MeSH terms
- Animals, Antipruritics, Chronic Disease, Humans, Pruritus, Quality of Life, Receptors, Neurokinin-1, Isoindoles, Neurokinin-1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. https://app.cochat.ai/papers/10.1080/13543784.2019.1638910
- The paper
- Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G. (2019). The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2019.1638910
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.